{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:47:39Z","timestamp":1769507259619,"version":"3.49.0"},"reference-count":98,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Cardiac amyloidosis (CA) is a progressive condition resulting from the deposition of amyloid fibrils in the heart, which leads to severe diastolic dysfunction and restrictive cardiomyopathy. The disease has two main subtypes: light-chain and transthyretin (TTR) CA, with the latter subdivided into wild-type and hereditary forms. Despite advances in diagnostic imaging, early detection remains a challenge due to non-specific symptoms that mimic other cardiac conditions. Treatment has evolved significantly with targeted therapies like TTR stabilizers, gene silencers, and RNA interference, showing promise in altering disease progression. However, barriers such as high costs, limited availability of genetic testing, and inadequate multidisciplinary care continue to impede comprehensive management. Future strategies should focus on integrating novel gene-editing therapies, expanding access to diagnostics, and enhancing multidisciplinary care models to improve outcomes. Overall, early diagnosis, equitable access to therapies, and personalized management plans are crucial to advancing care for CA patients.<\/jats:p>","DOI":"10.3390\/biomedicines13010079","type":"journal-article","created":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T14:35:42Z","timestamp":1735742142000},"page":"79","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancements in Cardiac Amyloidosis Treatment"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6292-7683","authenticated-orcid":false,"given":"Tarek Ziad","family":"Arabi","sequence":"first","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Shaik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Henry Ford St. John Hospital, Detroit, MI 48236, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"El-Shaer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Creighton University School of Medicine, Omaha, NE 68124, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-3261","authenticated-orcid":false,"given":"Omar","family":"Al Tamimi","sequence":"additional","affiliation":[{"name":"Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL 62702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2808-4656","authenticated-orcid":false,"given":"Eman Nayaz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7632-666X","authenticated-orcid":false,"given":"Mohamad S.","family":"Alabdaljabar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Safdar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-1665","authenticated-orcid":false,"given":"Ali","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1126\/science.174.4010.712","article-title":"Creation of \u201camyloid\u201d fibrils from Bence Jones proteins in vitro","volume":"174","author":"Glenner","year":"1971","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"Itc33","DOI":"10.7326\/AITC202303210","article-title":"Cardiac Amyloidosis","volume":"176","author":"Bloom","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Rapezzi","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: Recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac Amyloidosis Due to Transthyretin Protein: A Review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: Disproving myths","volume":"38","author":"Gagliardi","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jchf.2021.05.005","article-title":"Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS","volume":"9","author":"Caponetti","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.hfc.2024.02.002","article-title":"Pathophysiology of Cardiac Amyloidosis","volume":"20","author":"Morfino","year":"2024","journal-title":"Heart Fail. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cardfail.2022.08.008","article-title":"Atrial Fibrillation, Thromboembolic Risk, and Anticoagulation in Cardiac Amyloidosis: A Review","volume":"29","author":"Bukhari","year":"2023","journal-title":"J. Card. Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1093\/eurheartj\/ehac543","article-title":"Restrictive cardiomyopathy: Definition and diagnosis","volume":"43","author":"Rapezzi","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Robles","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hemminki, K., Li, X., F\u00f6rsti, A., Sundquist, J., and Sundquist, K. (2012). Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health, 12.","DOI":"10.1186\/1471-2458-12-974"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14\u2009333 African-Americans","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: Clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1161\/CIR.0000000000000455","article-title":"Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.hfc.2022.02.005","article-title":"Cardiac Amyloidosis","volume":"18","author":"Gertz","year":"2022","journal-title":"Heart Fail. Clin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","article-title":"AL Amyloidosis for Cardiologists","volume":"4","author":"Fontana","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s10741-021-10162-1","article-title":"Epidemiology and clinical manifestations of cardiac amyloidosis","volume":"27","author":"Bajwa","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to Image Cardiac Amyloidosis: A Practical Approach","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000508022","article-title":"Confirming the Diagnosis of Amyloidosis","volume":"143","author":"Wisniowski","year":"2020","journal-title":"Acta Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","article-title":"Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis","volume":"4","author":"Rapezzi","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11886-021-01564-6","article-title":"Multimodality Imaging in Cardiac Amyloidosis","volume":"23","author":"Giblin","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41569-020-0334-7","article-title":"Diagnostic imaging of cardiac amyloidosis","volume":"17","author":"Baksi","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s10741-023-10332-3","article-title":"Advance of echocardiography in cardiac amyloidosis","volume":"28","author":"Liang","year":"2023","journal-title":"Heart Fail. Rev."},{"key":"ref_31","first-page":"e000030","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e12967","DOI":"10.1111\/anec.12967","article-title":"Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis","volume":"27","author":"Ng","year":"2022","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"ref_33","first-page":"e000029","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0002-9149(87)90948-9","article-title":"Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis","volume":"59","author":"Falk","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jacc.2003.08.043","article-title":"Noninvasive diagnosis of biopsy-proven cardiac amyloidosis","volume":"43","author":"Rahman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ejhf.2200","article-title":"Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans","volume":"23","author":"Minamisawa","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1016\/j.echo.2022.06.006","article-title":"Practical Points for Echocardiography in Cardiac Amyloidosis","volume":"35","author":"Cuddy","year":"2022","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac Scintigraphy with Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week","volume":"75","author":"Hanna","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcmg.2013.09.019","article-title":"CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis","volume":"7","author":"White","year":"2014","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","article-title":"Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis","volume":"3","author":"Syed","year":"2010","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jcmg.2019.04.011","article-title":"Cardiac Magnetic Resonance T1 Mapping for Cardiac Amyloidosis: The Best Way Forward","volume":"13","author":"Karamitsos","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.mric.2019.04.005","article-title":"The Role of Cardiac MR Imaging in the Assessment of Patients with Cardiac Amyloidosis","volume":"27","author":"Carvalho","year":"2019","journal-title":"Magn. Reson. Imaging Clin. N. Am."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic Resonance in Transthyretin Cardiac Amyloidosis","volume":"70","author":"Treibel","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jcmg.2012.04.006","article-title":"Quantification of extracellular matrix expansion by CMR in infiltrative heart disease","volume":"5","author":"Mongeon","year":"2012","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1148\/radiol.2018172435","article-title":"Left Ventricular Myocardial Deformation on Cine MR Images: Relationship to Severity of Disease and Prognosis in Light-Chain Amyloidosis","volume":"288","author":"Wan","year":"2018","journal-title":"Radiology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13139-020-00681-4","article-title":"Nuclear Imaging for Cardiac Amyloidosis: Bone Scan, SPECT\/CT, and Amyloid-Targeting PET","volume":"55","author":"Paeng","year":"2021","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","article-title":"Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution","volume":"14","author":"Poterucha","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ejhf.2769","article-title":"N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis","volume":"25","author":"Vergaro","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis","volume":"5","author":"Takashio","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.mayocp.2021.04.023","article-title":"Artificial Intelligence-Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis","volume":"96","author":"Grogan","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"102860","DOI":"10.1016\/j.cpcardiol.2024.102860","article-title":"Artificial intelligence-enhanced electrocardiogram for the diagnosis of cardiac amyloidosis: A systemic review and meta-analysis","volume":"49","author":"Khan","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/s41467-021-22877-8","article-title":"Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms","volume":"12","author":"Goto","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S2589-7500(24)00024-4","article-title":"Artificial intelligence-driven cardiac amyloidosis screening","volume":"6","author":"Abdaem","year":"2024","journal-title":"Lancet Digit. Health"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"131813","DOI":"10.1016\/j.ijcard.2024.131813","article-title":"Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis","volume":"402","author":"Kang","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor Therapy in Patients with Transthyretin Amyloid Cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ejhf.2397","article-title":"Sodium\u2013glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/CRD.0000000000000306","article-title":"Tafamidis: A Novel Treatment for Transthyretin Amyloid Cardiomyopathy","volume":"28","author":"Nawarskas","year":"2020","journal-title":"Cardiol. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1253\/circj.CJ-19-0811","article-title":"A Statement on the Appropriate Administration of Tafamidis in Patients with Transthyretin Cardiac Amyloidosis","volume":"84","author":"Endo","year":"2019","journal-title":"Circ. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","article-title":"RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis","volume":"37","author":"Ioannou","year":"2023","journal-title":"BioDrugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10286-019-00626-8","article-title":"Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system","volume":"29","year":"2019","journal-title":"Clin. Auton. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients with Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy","volume":"392","author":"Fontana","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2023.11.016","article-title":"Effect of Eplontersen on Cardiac Structure and Function in Patients with Hereditary Transthyretin Amyloidosis","volume":"30","author":"Masri","year":"2024","journal-title":"J. Card. Fail."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2024.01.001","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","volume":"123","author":"Porcari","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid","volume":"389","author":"Donal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-Associated Reversal of ATTR Amyloidosis-Related Cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/hum.2021.013","article-title":"CRISPR\/Cas-Dependent and Nuclease-Free In Vivo Therapeutic Gene Editing","volume":"32","author":"Dasgupta","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ajh.26569","article-title":"Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment","volume":"97","author":"Gertz","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded Cardiac Response Criteria for Patients with Systemic Light Chain Amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4065\/mcp.2010.0480","article-title":"Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score","volume":"86","author":"Kumar","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood.2022016348","article-title":"Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival","volume":"140","author":"Basset","year":"2022","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood","year":"2014","journal-title":"Haematologica"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: The phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","article-title":"2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis","volume":"23","author":"Renz","year":"2016","journal-title":"Amyloid"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"key":"ref_94","first-page":"3831s","article-title":"Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4","volume":"9","author":"Solomon","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e2801725","DOI":"10.1097\/01.HS9.0000967728.28017.25","article-title":"S204: Safety and tolerability of CAEL-101, an anti-amyloid monoclonal antibody, combined with anti-plasma cell dyscrasia therapy in patients with light-chain amyloidosis: 18-month results of a phase 2 study","volume":"7","author":"Valent","year":"2023","journal-title":"HemaSphere"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/ehf2.13443","article-title":"Progress and challenges in the treatment of cardiac amyloidosis: A review of the literature","volume":"8","author":"Adam","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"\u00c7avu\u015fo\u011flu, Y., Ba\u015far\u0131c\u0131, \u0130., T\u00fcfek\u00e7io\u011flu, O., \u00d6zpelit, E., \u00d6zdemir, E., Sivrikoz, \u0130.A., Altay, H., De\u011fertekin, M., Din\u00e7er, \u0130., and \u0130kitimur, B. (2024). Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: A Delphi study. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1299261"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Morgan, G.J. (2021). Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis. Molecules, 26.","DOI":"10.20944\/preprints202104.0270.v1"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/1\/79\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:58:12Z","timestamp":1760115492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/1\/79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["biomedicines13010079"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13010079","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}